Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0948265 (
metabolic syndrome
)
24,271
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activation of the vascular
endothelin-1
(
ET-1
) system is a key abnormality in vascular dysfunction of human obesity, especially in patients developing complications, such as the
metabolic syndrome
, diabetes, and atherosclerosis. Vascular insulin resistance, an increased insulin-stimulated endothelial production of
ET-1
combined with impaired nitric oxide availability, is the hallmark of obesity-related vasculopathy, but dysregulated adipokine release from obese adipose tissue may contribute to the predominance of
ET-1
-dependent vasoconstriction.
ET-1
, in turn, might determine unhealthy obese adipose tissue expansion, with visceral and perivascular adipose tissue changes driving the release of inflammatory cytokines and atherogenic chemokines. In addition,
ET-1
might also play a role in the development of the metabolic complications of obesity. Studies have shown inhibition of lipoprotein lipase activity by
ET-1
, with consequent hypertriglyceridemia. Also,
ET-1
in pancreatic islets seems to contribute to beta cell dysfunction, hence affecting insulin production and development of diabetes. Moreover,
ET-1
may play a role in nonalcoholic steatohepatitis. Recent clinical trials using innovative design have demonstrated that antagonism of ET-type A receptors protects against some complications of obesity and diabetes, such as nephropathy. These findings encourage further investigation to evaluate whether targeting the
ET-1
system could afford better protection against other consequences of the obesity epidemic.
...
PMID:Intricacies of the endothelin system in human obesity: role in the development of complications and potential as a therapeutic target. 3280 24
<< Previous
1
2
3
4
5
6
